A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies (REMERGE)

NCT06274515 PHASE4 RECRUITING

This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE4
Status	RECRUITING
Enrolment	320
Start date	Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Breast Cancer

Interventions

• Tumor Tissue and Blood Draw

Countries

Denmark, Italy, Finland, Belgium, United Kingdom, Germany, Norway, Spain